Ian McLaren, MD
Urology · Wenatchee, WANPI 1215290705
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 76.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $1,637, more than ten times the $38 reported in 2019. That places this record below the midpoint for urology clinicians in WA, where the typical reported total is $1,712.
Across 33 payments — averaging $62.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Axonics, Inc.$299
- 180 Medical, Inc.$59
- Laborie Medical Technologies Corp.$58
- Coloplast$28
- Medtronic$23
- plus $19 from 2 others
What the payments were for
- Travel & lodging$1,23259%
- Food & beverage$84241%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 9 | $1,593 |
| Axonics, Inc. | 14 | $299 |
| 180 Medical, Inc. | 2 | $59 |
| Laborie Medical Technologies Corp. | 3 | $58 |
| Coloplast | 2 | $28 |
| Medtronic | 1 | $23 |
| AbbVie | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solyx SIS System$1,430
How this compares
$2,078 in reported general payments places this provider in the 50th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 39 | $29,159 |
| Tamsulosin Hcl | 73 | $1,162 |
| Finasteride | 69 | $841 |
| Cefpodoxime Proxetil | 32 | $571 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $271 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $231 |
| Cephalexin | 28 | $119 |
| Levofloxacin | 30 | $58 |
| Oxycodone Hcl | 17 | $35 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other urology in Wenatchee
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.